Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsCritical Assessment of Clinical Prognostic Tools in Melanoma.Analysis of survival data with missing measurements of a time-dependent binary covariate.Independent data monitoring committees: an update and overviewResidential mercury contamination in adobe brick homes in Huancavelica, Peru.Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Adjusting for misclassification in a stratified biomarker clinical trial.The importance of identifying and validating prognostic factors in oncology.A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome.Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate CancerRandomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.Reply to B. Rini et al and S. Buti et al.Activities and accomplishments of the cancer and leukemia group B genitourinary committee.A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease.Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.High Dimensional Variable Selection with Error ControlOn model specification and selection of the Cox proportional hazards model.Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapyPrognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
P50
Q24599547-809B5A75-7E96-458D-8005-44FB778D5A61Q30251644-888137BE-A8FE-4A57-945D-D944076ADE64Q30790798-0C6F664A-1A9E-4D35-BEFB-C67E3644F3EDQ30886528-45E2C603-44A9-43CB-9B3C-C32DDD4BA934Q31139555-9F79C5DE-4F7A-488F-936A-1A088AA46825Q33341148-AE8630B8-63D7-4EBE-A302-75DD30FFFF38Q33358093-99965C58-0913-4E32-944A-ECDE03D3B8D2Q33566395-A746E926-6D72-4C48-83DF-A9F29B520779Q33767866-B1BD5093-3DBC-42D7-9972-C9B1A66EB9C1Q33813718-C353FD98-42E6-4F3E-9AEE-0D3F7A27483CQ33934232-D676E497-4503-4E3A-8026-5D94952FC54CQ34090548-EDD79105-3428-4D16-9617-3C106E0D690AQ34441553-39474845-517A-4AB9-8E37-0A6CAF33EA27Q34730135-FB2B283B-3FB2-408E-9C6E-606AC1BEC5F0Q35202464-B247EC64-AB93-43D8-B116-C33D3B70192BQ35855330-42C0556E-9E69-48BF-BD4C-6890A1BE2EB7Q35879087-275F323D-9BC8-48D8-9215-25EEAE1A8B9EQ35948297-53638D6C-D247-4AF1-9C80-7412A61AC933Q36058291-3DD949BD-3437-47D8-B8A5-7493AE12424AQ36258014-173F4DD1-B60A-4AFE-8D86-A6D9F7EE505AQ36281483-2E2ABF7B-FC07-4760-96AB-D84E2BA86AA8Q36382934-470DE310-4676-4325-9975-83C2DB3BCB7BQ36494901-BC1A7CD3-3C9C-479E-932A-A1953F1E03E9Q36540983-F9E55449-EF8E-48E3-9ABD-A3C1C9FF5BEBQ36563715-01523946-B657-4C60-AB82-ECD406B10984Q36799870-7CBB8511-F342-449F-9A3D-5B732928C636Q37153022-6744C478-0559-4390-A5E5-FE07527D2B60Q37212655-CB2EC27E-DBF0-4512-A770-8CA72159AAF0Q37227787-B0E31B39-C433-48F7-B17E-C9FB3E1B2313Q37231510-D8040EE4-43F7-4F5F-8084-5E242E75F2DCQ37249358-2487F373-8C4C-4030-923D-E73F68091318Q37325001-750BBC6B-4C5F-490A-959B-44D89BC6957FQ37590738-F0A1C9D1-7A98-4B94-A377-7FB9ADB8FB9EQ38593365-3AF3FF11-C7E2-4457-BF04-2E2471DE2BC4Q38607675-24013F5F-9BA1-46F6-B6DA-EED286BB07B2Q38647041-1D037EE1-88B4-45E4-B963-291A3D693FDEQ38684115-6A392B57-8265-41FC-ADE1-13B471A5AC92Q38706310-80C57A0C-D2E7-4FF9-8CAB-878CAB099F4CQ38917870-00C8CF5F-9DBC-4C37-AA9B-92CD4FA7F910Q39796533-B4B0CA76-2AC2-494C-ABEA-7FBDE9BE53E5
P50
description
Amerikaans statistica
@nl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Susan Halabi
@ast
Susan Halabi
@en
Susan Halabi
@es
Susan Halabi
@fr
Susan Halabi
@nl
Susan Halabi
@sl
type
label
Susan Halabi
@ast
Susan Halabi
@en
Susan Halabi
@es
Susan Halabi
@fr
Susan Halabi
@nl
Susan Halabi
@sl
prefLabel
Susan Halabi
@ast
Susan Halabi
@en
Susan Halabi
@es
Susan Halabi
@fr
Susan Halabi
@nl
Susan Halabi
@sl
P106
P1015
P214
P244
P269
P1015
P108
P1412
P1556
halabi.susan
P21
P213
0000 0003 8453 5995
P214
P244
n2009184488
P269
P31
P496
0000-0003-4135-2777
P549
P734
P735
P7859
lccn-n2009184488